Peps
What is TRH (thyrotropin-releasing hormone)?
TRH is one of the body's own hormones: a tiny peptide made in the brain that tells the pituitary gland to release thyroid-stimulating hormone. A synthetic version, protirelin, was long used in a hospital test of thyroid and pituitary function. Researchers have also studied it in small trials for fatigue, depression and nerve diseases.
Biological role or research focus
Thyroid testing history and small trials for fatigue, mood and nerve conditions.
Only eight patients completed the study, effects were measured over hours to a day, and no larger trial has confirmed the result. It does not show benefit for fatigue in people without cancer or with longer use.
Role reference: Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study · 2012 ↗
Names you may encounter
TRH · Thyrotropin-releasing hormone · Protirelin · Thyroliberin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Natural three-amino-acid brain peptide (pGlu-His-Pro-NH2) that signals the pituitary to release thyroid-stimulating hormone
- Research focus
- Thyroid testing history and small trials for fatigue, mood and nerve conditions
- Featured evidence
- Human randomized crossover pilot trial
- Source check
- October 4, 2026
Biology & proposed mechanism
Beyond its thyroid role, TRH acts on receptors elsewhere in the brain, where it has alerting, mood-lifting effects in short studies. It breaks down within minutes in the body, which is one reason it never became a routine treatment.
Research context & identity
This profile covers TRH as a hormone and research topic. Its main historical medical use was diagnostic (the TRH stimulation test), which has largely been replaced by modern blood tests. Small studies have explored it for cancer-related fatigue, depression and spinal muscular atrophy; none established it as a treatment.
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| TRH for cancer-related fatigue (2012) | Human randomized crossover pilot trial | Eight adults with cancer and significant fatigue without a reversible medical cause. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized crossover pilot trial · 2012
TRH for cancer-related fatigue
What did this publication test, and what did it find?
- Population / model
- Eight adults with cancer and significant fatigue without a reversible medical cause.
- Study design
- Pilot randomized, placebo-controlled crossover study: each patient received TRH and placebo in random order, with energy rated at 3, 7 and 24 hours, plus mood, walking, sleep and quality-of-life measures.
- Main finding
- Energy ratings and the fatigue and vigor scores improved with TRH compared with placebo, along with fatigue-related quality of life. TRH caused brief rises in blood pressure and heart rate.
- Limits & context
- Only eight patients completed the study, effects were measured over hours to a day, and no larger trial has confirmed the result. It does not show benefit for fatigue in people without cancer or with longer use.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
7 registered studies name TRH (thyrotropin-releasing hormone) as an intervention; 0 are recruiting or active and 5 completed. Checked October 8, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety & what remains unknown
In studies, TRH caused short-lived rises in blood pressure and heart rate; in diagnostic testing it can cause flushing, nausea and an urge to urinate. Because it acts on the thyroid axis, it can disturb thyroid and pituitary hormone levels and should not be used outside medical care.
Evidence boundaries
Only eight patients completed the study, effects were measured over hours to a day, and no larger trial has confirmed the result. It does not show benefit for fatigue in people without cancer or with longer use.
Regulatory status
- U.S. FDA approval
- Approved, now discontinued
Protirelin products Thyrel TRH (NDA 018087) and Thypinone (NDA 017638), diagnostic agents for thyroid function testing, are both listed in Drugs@FDA as discontinued. source - FDA compounding (503A bulk list)
- Not on the lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Not on the lists
Not named and not within a prohibited class on the 2026 List. source
Checked October 8, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides, Peptide.Express, Offline Peptides, Alera Research, Pinnacle Peptide Labs. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is TRH a thyroid hormone?
- What material, population, and route were actually studied?
- Only eight patients completed the study, effects were measured over hours to a day, and no larger trial has confirmed the result. It does not show benefit for fatigue in people without cancer or with longer use.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is TRH a thyroid hormone?
Not exactly. TRH is the brain signal that starts the thyroid chain: it prompts the pituitary to release TSH, which then tells the thyroid to make its hormones. It is studied separately from thyroid hormone itself.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.